The aim is to determine if anitplatelet montherapy is of overall net benefit in reducing the incidence of serious vasulat events compared to avoiding antiplatelet therapy for adults with a history of a previous stroke due to spontaneous (non-traumatic) intracerebal hamorrhage (ICH). The study design is an investigator led, multicentre, prosepective, randomised, open-label, blinded outcome (Probe), parallel-group clinical trial. The primary outcome is the composite of all serious vascular events (non-fatal stroke [including ICH], non-fatal myocardial infarction, or death from a vascular cause). The expected outcome is that surviors of spontaneous (non-traumatic) ICH will be shown to have vascular disease(s) that predispose(s) them to future vaso-occlusive, ischaemic vascular events, which can be reduced by prophylactic antiplatelet therapy without increased rsik of reccurrent ICH.